黄作超, 曾春生, 康昭洵, 吕根梅, 叶红梅, 陈小妹, 王菊平, 肖雅丽. 金龙胶囊联合化疗治疗晚期非小细胞肺癌患者的临床观察[J]. 中国肿瘤临床, 2012, 39(24): 2104-2107. DOI: 10.3969/j.issn.1000-8179.2012.24.029
引用本文: 黄作超, 曾春生, 康昭洵, 吕根梅, 叶红梅, 陈小妹, 王菊平, 肖雅丽. 金龙胶囊联合化疗治疗晚期非小细胞肺癌患者的临床观察[J]. 中国肿瘤临床, 2012, 39(24): 2104-2107. DOI: 10.3969/j.issn.1000-8179.2012.24.029
shu
Zuochao HUANG, Chunsheng CENG, Zhaoxun KANG, Genmei LV, Hongmei YE, Xiaomei CHEN, Juping WANG, Yali XIAO. Clinical Observation of Advanced Non-small Cell Lung Cancer Treated by Jinlong Capsule and Chemotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(24): 2104-2107. DOI: 10.3969/j.issn.1000-8179.2012.24.029
Citation: Zuochao HUANG, Chunsheng CENG, Zhaoxun KANG, Genmei LV, Hongmei YE, Xiaomei CHEN, Juping WANG, Yali XIAO. Clinical Observation of Advanced Non-small Cell Lung Cancer Treated by Jinlong Capsule and Chemotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(24): 2104-2107. DOI: 10.3969/j.issn.1000-8179.2012.24.029
shu

金龙胶囊联合化疗治疗晚期非小细胞肺癌患者的临床观察

Clinical Observation of Advanced Non-small Cell Lung Cancer Treated by Jinlong Capsule and Chemotherapy

    摘要
  • 摘要:
      目的  观察金龙胶囊对提高晚期非小细胞肺癌（NSCLC）患者化疗临床受益反应率、改善免疫功能、降低不良反应率的影响。
      方法  将经病理学检查确诊的56例ⅢB期和Ⅳ期的NSCLC患者随机分为2组，单纯化疗组（对照组）和化疗联合金龙胶囊组（治疗组）各28例。所有患者至少完成3个周期化疗，3周期后观察患者临床受益反应率、免疫功能、不良反应发生率。
      结果  治疗组体重≥7%者15例，占53.5%（15/28），对照组体重≥7%者13例，占46.4%（13/28），两组比较无显著性差异（P>0.05）。治疗组Karnofsky评分提高≥20分者16例，占57.1%（16/28），对照组Karnofsky评分提高≥20分者10例，占35.7%（10/28），两组比较有显著性差异（P < 0.05）。治疗组吗啡类止痛药用量减少≥50%者13例，占46.4%（13/28），对照组吗啡类止痛药用量减少≥50%者7例，占25%（7/28），两组比较有显著性差异（P < 0.05）。治疗组不良反应发生率57.1%，对照组75%，两组比较有显著性差异（P < 0.05）。
      结论  金龙胶囊联合化疗治疗晚期NSCLC患者的临床受益率较高，能显著改善患者对化疗的耐受性，提高其用药依从性，且安全性较好，值得推广。

     

    Abstract:
      Objective  This study aims to observe the impacts of Jinlong capsule on the clinical benefit response rate, immune function, and incidence of adverse reactions for patients with advanced non-small cell lung cancer (NSCLC) treated with chemotherapy.
      Methods  A total of 56 cases suffering from stage ⅢB or Ⅳ NSCLC who were confirmed by pathology were randomly divided into 2 groups, including 28 cases of pure chemotherapy group (comparison group) and 28 cases treated with chemotherapy combined with Jinlong capsule (treatment group). After the patients completed at least three cycles of chemotherapy, the clinical benefit response rate, immune function, and incidence of adverse reactions were observed
      Results  The weight ≥7% of the treatment group were 15 cases (53.5%), whereas that of the comparison group were 13 cases (46, 4%); no significant difference was observed between the two groups (P>0.05). A significant difference between the two groups was observed with the increase in Karnofskyp score ≥20 (P < 0.05). The rate of the treatment group was 57.1% (16 cases), whereas that of the comparison group was 35.7% (10 cases). The rate of the opioids dosage reduction ≥50% in the treatment group was 46.4% (13cases), whereas that in the comparison group was 25% (7 cases); significant difference was observed between the two groups (P < 0.05).
      Conclusions  The clinical benefit response rate of chemotherapy combined with Jinlong capsule for advanced NSCLC patients was higher than that with chemotherapy alone. In addition this combination treatment can improve chemotherapy tolerance of patients; the medicine compliance also has higher safety. Therefore, this combination treatment is worthy to popularize in clinical applications.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回